Loading…
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-169M | $-161M | $-139M | -35.2% | - | - |
| 2024 | $0M | $0M | $0M | - | 0.0% | - | - |
| 2023 | $0M | $0M | $0M | - | 0.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Revenue | 0 | 0 | 0 |
| Operating Expense | 0 | 0 | 169.08 |
| Operating Income | 0 | 0 | -169.08 |
| EBITDA | 0 | 0 | -168.50 |
| EBIT | 0 | 0 | -169.08 |
| Pretax Income | 0 | 0 | -161.15 |
| Net Income | 0 | 0 | -161.15 |
| Net Income Common Stockholders | 0 | 0 | -161.15 |
| Total Expenses | 0 | 0 | 169.08 |
| Interest Income | 0 | 0 | 5.52 |
| Research And Development | 0 | 0 | 138.35 |
| Selling General And Administration | 0 | 0 | 30.73 |
| Normalized EBITDA | -56.73 | 0 | -168.50 |
| Normalized Income | -55.71 | 0 | -161.15 |
| Basic EPS | 0 | -2.96 | 0 |
| Diluted EPS | 0 | -2.96 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | 0 | 0 | -161.15 |
| Reconciled Depreciation | 0 | 0 | 0.58 |
| Net Interest Income | 0 | 0 | 5.52 |
| Net Income From Continuing And Discontinued Operation | 0 | 0 | -161.15 |
| Total Operating Income As Reported | 0 | 0 | -169.08 |
| Diluted Average Shares | 0 | 26.18 | 0 |
| Basic Average Shares | 0 | 26.18 | 0 |
| Diluted NI Availto Com Stockholders | 0 | 0 | -161.15 |
| Net Income Including Noncontrolling Interests | 0 | 0 | -161.15 |
| Net Income Continuous Operations | 0 | 0 | -161.15 |
| Other Income Expense | 0 | 0 | 2.41 |
| Other Non Operating Income Expenses | -0.51 | 0 | 2.41 |
| Earnings From Equity Interest | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0 | 0 | 5.52 |
| Interest Income Non Operating | 0 | 0 | 5.52 |
| General And Administrative Expense | 0 | 0 | 30.73 |
| Other Gand A | 0 | 0 | 9.05 |
| Salaries And Wages | 0 | 0 | 21.69 |
| Operating Revenue | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MapLight Therapeutics, Inc.this co. | MPLT | $1.3B | - | 2.91 | -35.2% | -6.14 |
| MBX Biosciences, Inc. | MBX | $1.4B | - | 3.48 | -23.6% | -10.08 |
| Clover Health Investments, Corp. | CLOV | $1.4B | - | 4.34 | -27.7% | -14.49 |
| Wave Life Sciences Ltd. | WVE | $1.4B | - | 2.55 | -39.4% | -4.28 |
| Novavax, Inc. | NVAX | $1.3B |
| 3.09 |
| -10.14 |
| -344.7% |
| 1.42 |
| Butterfly Network, Inc. | BFLY | $1.3B | - | 6.37 | -39.3% | -20.73 |
| PROCEPT BioRobotics Corporation | PRCT | $1.2B | - | 3.34 | -26.1% | -10.43 |
| Olema Pharmaceuticals, Inc. | OLMA | $1.2B | - | 2.40 | -33.9% | -4.35 |
| Corvus Pharmaceuticals, Inc. | CRVS | $1.2B | - | 17.61 | -25.0% | -26.95 |
| Peer Median | - | 3.09 | 3.41 | -30.8% | -10.25 | |